Zacks Investment Research upgraded shares of FLEXION THERAPT (FLXN) from NEUTRAL to OUTPERFORM on January 19, 2015, with a target price of $24.60.
Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on FLEXION THERAPT (FLXN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment